Skip to main content
Fig. 2 | Genome Medicine

Fig. 2

From: High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine

Fig. 2

Phenotypic characterisation of peripheral blood plasma cells (PBMCs) following immunisation. Purified, CD19+ B cells were labelled for identification of plasma cells at baseline (day 0) and 7 days post first (day 7) and second dose (day 35). Representative plots (group 1 participant) of CD38hiCD27hi plasma cells (a) and CXCR3 HLA-DR subsets (b) are shown for days 0, 7 and 35, with day 28 included to demonstrate a return to baseline prior to the second dose. The overall frequencies of total CD38hiCD27hi plasma cells per group (c) and CXCR3 HLA-DR subsets (d) at baseline and 1 week after each vaccine dose are shown per group. Data are expressed as percentage of total B cells, with bars showing median frequency (interquartile range). ANOVA were performed within each group and the significant differences are denoted (*p = <0.05). Group 1, MenACWY-CRM/MenACWY-CRM; group 2, MenACWY-PS (intramuscular)/MenACWY-CRM; group 3, MenACWY-PS (subcutaneous)/MenACWY-CRM; group, MenACWY-PS (one-fifth dose intramuscular)/MenACWY-CRM. e Proportion of plasma cell subsets (percentage of total) at each study time point for the conjugate group 1 (n = 5) and polysaccharide groups 2, 3 and 4 (combined, n = 14)

Back to article page